12May
Astra Zeneca. “Lynparza” is a light at the end of the tunnel for triple-negative breast cancer.
The FDA has approved the first drug against the mortal type of breast cancer. Lynparza, unlike its predecessors, treats HER2/neu negative cancer, which has been increasing in the last years, giving hope to patients suffering from this terrible disease.
